Filing Flows

Filing Flows › Companies › Theriva Biologics › Cash flow

Theriva Biologics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$3.1M in Q2 2026 · −$12.8M over twelve months

Operating cash flow−$3.1M
Free cash flow−$3.1M

Analysis

In Q2 2026, Theriva Biologics generated −$3.1M of operating cash flow. That is $1.6M more than in Q2 2025 (−$4.7M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$12.7M; the largest uses were operating cash flow ($12.7M), capital spending ($22K); besides operations, cash came from other financing ($12.2M); the cash balance fell by $785K.

Operating cash flow was −$3.1M against net income of −$3.2M. The largest differences: payables +$389K, accrued liabilities +$223K, stock-based pay +$135K.

Free cash flow

Theriva Biologics: free cash flow by quarterTheriva Biologics: free cash flow by quarter−$3.9MQ3 2024−$4.7MQ4 2024−$4.8MQ1 2025−$4.7MQ2 2025−$4.3MQ3 2025−$2.9MQ4 2025−$2.5MQ1 2026−$3.1MQ2 2026
Operating cash flow less capital spending.
Theriva Biologics: operating cash flow against capital spendingTheriva Biologics: operating cash flow against capital spendingOperating cash flowCapital spending−$3.9M$0Q3 2024−$4.7M$0Q4 2024−$4.8M$0Q1 2025−$4.7M$0Q2 2025−$4.3M$19KQ3 2025−$2.9M$0Q4 2025−$2.5M$0Q1 2026−$3.1M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$3.1M, Capital spending $0.

Capital allocation, year by year

Theriva Biologics: where the cash came from (up) and went (down), by fiscal yearTheriva Biologics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow −$12.9MFY2021: Shares issued $66.0MFY2021: Capital spending −$14K$66.0MFY2021FY2022: Operating cash flow −$19.1MFY2022: Net borrowing −$1.4MFY2022: Capital spending −$116KFY2022: Acquisitions −$3.9MFY2022: Buybacks −$288KFY2022FY2023: Operating cash flow −$19.0MFY2023: Net borrowing −$75KFY2023: Capital spending −$202KFY2023FY2024: Operating cash flow −$16.9MFY2024: Net borrowing −$67KFY2024: Capital spending −$1KFY2024FY2025: Operating cash flow −$16.7MFY2025: Net borrowing $1.5MFY2025: Capital spending −$35K$1.5MFY2025
Over these 5 years operating cash flow totalled −$84.6M; the largest uses were operating cash flow ($84.6M) and acquisitions ($3.9M). Cash-flow statements as filed.

Where the cash came from and went

Theriva Biologics: sources (+) and uses (−) of cash, Q2 2026Theriva Biologics: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$3.1MOperating cash flow−$3.1MOther financing−$14KExchange rates$7KNot reconciled−$3K
Theriva Biologics: sources (+) and uses (−) of cash, TTM to Q2 2026Theriva Biologics: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$12.7MOther financing$12.2MCash drawn (+) / kept (−)$785KExchange rates−$183KCapital spending−$22K

From profit to cash

Theriva Biologics: net income to operating cash flow, Q2 2026Theriva Biologics: net income to operating cash flow, Q2 2026Net income−$3.2MDepreciation & amortization$24KStock-based pay$135KPayables$389KAccrued liabilities$223KEmployee-related liabilities$25KPrepaid and other assets−$26KOperating cash flow−$3.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q2 2026−$3.1M——$3.1M−$3.1M
Q1 2026−$2.5M——−$1.4M−$2.5M
Q4 2025−$2.9M—$15K−$5.5M−$2.9M
Q3 2025−$4.3M−$19K$34K$4.6M−$4.3M
Q2 2025−$4.7M—$57K−$2.1M−$4.7M
Q1 2025−$4.8M—$1.3M$1.6M−$4.8M
Q4 2024−$4.7M——$4.8M−$4.7M
Q3 2024−$3.9M——$180K−$3.9M

Theriva Biologics: income statement and cash flow

Theriva Biologics, Q1 2026: revenue $300K, operating margin -709.0%. The chart follows the revenue to costs, profit and cash.

Theriva Biologics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.